FDA Approved: IMATINIB MESYLATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

FDA approves Teva's supplemental application for imatinib mesylate, a generic version of the cancer drug, to update its approval status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia
• Dermatofibrosarcoma Protuberans
• Gastrointestinal Stromal Tumor
• Myeloid Lymphoid Neoplasm with Eosinophilia and Pdgfra Rearrangement
• Myeloid Lymphoid Neoplasm with Eosinophilia and Pdgfrb Rearrangement

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

SUPPL AP for IMATINIB MESYLATE (IMATINIB MESYLATE)